Quest Diagnostics
About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Employees: 56,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
41% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 83
11% more capital invested
Capital invested by funds: $17.2B [Q1] → $19.2B (+$1.98B) [Q2]
11% more repeat investments, than reductions
Existing positions increased: 357 | Existing positions reduced: 323
4.06% more ownership
Funds ownership: 91.84% [Q1] → 95.91% (+4.06%) [Q2]
1% more funds holding
Funds holding: 952 [Q1] → 966 (+14) [Q2]
33% less call options, than puts
Call options by funds: $88.3M | Put options by funds: $133M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Baird
Eric Coldwell
|
$194
|
Neutral
Downgraded
|
25 Aug 2025 |
|
UBS
Kevin Caliendo
|
$180
|
Neutral
Maintained
|
23 Jul 2025 |
|
Truist Securities
David Macdonald
|
$192
|
Hold
Maintained
|
23 Jul 2025 |
|
Deutsche Bank
Pito Chickering
|
$178
|
Hold
Maintained
|
23 Jul 2025 |
Financial journalist opinion
Based on 12 articles about DGX published over the past 30 days
